First National Advisers LLC Reduces Stock Holdings in Zoetis Inc. $ZTS

First National Advisers LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 91.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,765 shares of the company’s stock after selling 28,062 shares during the period. First National Advisers LLC’s holdings in Zoetis were worth $348,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC lifted its position in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co lifted its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.3%

NYSE ZTS opened at $76.92 on Wednesday. The stock has a 50 day moving average price of $115.42 and a 200-day moving average price of $122.28. Zoetis Inc. has a one year low of $75.11 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market capitalization of $32.25 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.25 and a beta of 0.87.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.9 EPS for the current fiscal year.

Insider Activity at Zoetis

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZTS. Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a research note on Friday. Citigroup initiated coverage on shares of Zoetis in a report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. UBS Group decreased their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday. JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $141.25.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.